Management team

Home / Team / Management team
Partner

Alexey Konov

  • MSU (1989); Ph.D., molecular biology, University Louis Pasteur, France (1998)
  • 20 years of overall experience in management and life sciences, including 8 years of venture investment experience ("Bioprocess Capital Ventures")
  • Board member at Retrosense Therapeutics, LLC (acquired by NYSE:AGN) and Bonti Inc. (acquired by NYSE:AGN)
Partner

Robert Karl

  • Fachhochschule München (1992)
  • Ex-Mallinckrodt Pharmaceuticals, commercial VP for Russia/CIS, Turkey, Middle East, Latin America (except Brazil), Australia and New Zealand
  • Over 20 years of work experience in the pharmaceutical industry, including executive roles at Schering Plough, MSD and Covidien AG
Head of Project Analysis

Ivan Olovnikov

  • MSU (2007), Caltech (2010-2013), Ph.D., molecular biology (2013)
  • Over 10 years of work experience in life sciences and industry (Russia, USA, Australia).
  • Co-founder of a biotech startup. Author of 20 scientific publications
Investment director

Igor Gonikhin

  • LSE and Higher School of Economics (2008)
  • 10 years of experience in private equity (Da Vinci Capital) and corporate finance advisory (Deloitte & Touche)
  • Expertise in leading investment deals in financial, tech and IT sectors
Medical Adviser

Sergey Grishin

  • RSMU (2003); Ph.D. in clinical pharmacology and psychiatry, State Institute of Pharmacology n.a. Zakusov (2008)
  • 10 years of experience in clinical development of novel medicinal products, scientific and medical affairs, drug safety and pharmacovigilance in academia and pharmaceutical industry (Lundbeck, R-Pharm)
  • Head of Scientific Affairs Group,
    R-Pharm
Scientific analyst

Sophia Zarubina

  • MSU Faculty of Chemistry (2014), PhD in Chemistry from MSU
  • 6 years of scientific experience in biochemistry and genetics
  • Engaged in analyzing biotechnological companies and market trends
Scientific analyst

Alexander Martynov

  • MSU Faculty of Bioengineering and Bioinformatics (2013), visiting PhD student at HMS and MIT, PhD from Skolkovo Institute of Technology
  • Founder of two start-ups (computational assessment of drugs, emotion recognition)
  • Engaged in the assessment of companies at the intersection of biotech and IT